Study guide
21.2 Equipment, Maintenance and Study Supplies
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
21.2 Equipment, Maintenance and Study Supplies
Key Takeaways Explain This Topic AI
Equipment suitability depends on intended use, configuration and relevant accuracy controls.
Out-of-calibration findings need assessment of affected historical measurements.
Supply planning should consider usability, expiry and timing rather than box count alone.
Last updated: October 2026
Equipment, Maintenance and Study Supplies
Equipment and supplies affect both participant safety and measurement reliability. The ECO includes equipment use and maintenance, ongoing calibration and management of study supplies. A CRA should verify the actual protocol requirements, suitable equipment, trained users and continued control. A calibration sticker is useful evidence, but it is not the whole assessment of whether a critical measurement is trustworthy.
Start with intended use: what is measured or performed, required accuracy/range, operating conditions, compatible consumables and relevant software/configuration. Determine who owns and maintains the equipment, what checks are required, who receives failure alerts and what backup is available. Not every site needs the same equipment or service interval. Apply the protocol, manufacturer instructions and applicable quality process.
Qualification and records
Identify the equipment so service records can be linked to actual use. Relevant evidence can include an identifier, installation/acceptance checks, calibration or maintenance records, operating instructions, user training and changes. The extent depends on risk and intended use. A device used only for a low-impact administrative purpose does not necessarily need the same controls as a primary-endpoint instrument.
- Control Question Evidence example
- Identity Which instrument produced the result? Equipment ID linked to source/output
- Suitability Does it meet the protocol's intended use? Required range, configuration and acceptance evidence
- Maintenance Was it functioning as expected at the relevant time? Service/inspection records and issue history
- Calibration Were required accuracy checks current? Traceable calibration/check evidence where applicable
- Competence Could the operator perform the task? Task training and any required certification
- Continuity What happens if it fails? An appropriate tested backup or response process
Avoid inventing universal requirements such as a generator for every storage unit, a specific national calibration body for every device, or an identical annual service schedule. Those may be appropriate under a particular study plan. The underlying question is whether the controls manage the actual risk adequately and whether staff follow them.
Equipment failure during conduct
Suppose a primary-endpoint scale is discovered to be out of calibration. Identify the instrument, last acceptable check, detection date, relevant use and affected measurements. Notify the investigator and sponsor/technical function. Determine whether continued use should stop and whether a qualified replacement or other protocol-permitted option exists. Preserve the original results and relevant evidence.
An apparently reassuring calibration after repair does not prove every historical result was accurate. The responsible team evaluates the likely impact and whether supported correction, repeat measurement or a limitation is appropriate. A repeat months later cannot recreate the original observation. The CRA documents the investigation and verifies implementation of the agreed response without inventing adjusted historical values.
Supplies and expiry
Laboratory kits, collection materials, study devices and product-related supplies should be available in the right type and quantity when needed. Verify kit versions, relevant expiry dates, storage and compatibility. Similar packaging can hide different tubes or components. Staff should not substitute an ordinary clinic supply for a protocol-specific item without appropriate evaluation and authorisation.
Forecast needs from planned visits, expected recruitment, lead times and contingency requirements. A simple inventory can identify units on hand, allocated/used, expired, damaged and awaiting replacement. Keep those states distinguishable. A delivery receipt establishes arrival, not that the shipment is complete, undamaged and suitable for use.
For an illustrative stock example, a site has 12 usable kits, expects 8 scheduled collections before resupply and reserves 2 for permitted repeats. The planned requirement is 10, leaving a margin of 2 kits. If 3 current kits will expire before those visits, usable stock for the plan is only 9, leaving a shortage of 1. These are hypothetical numbers; the point is to consider time and usability rather than total boxes alone.
Configuration and software changes
A study instrument or tablet may receive updates affecting data capture, calculation or transmission. Use controlled change procedures and involve the responsible technical function. Document the version, timing, relevant testing and affected records. Do not disable updates or install a new algorithm independently just to make the next visit possible. Assess both data quality and security considerations.
Participant-provided or home-use equipment also needs appropriate instruction, support, traceability and contingency. Clarify return and data-preservation arrangements before closure. Returning a device should not delete the only source record or leave the participant without required ongoing care support.
Monitoring follow-up
During qualification assess the proposed capability; at initiation verify readiness; during conduct examine ongoing use, maintenance and problems; at close-out confirm suitable disposition and record retention. A failure found late can reveal earlier affected work, so follow the evidence across the lifecycle. Link any corrective action to a real process: ownership of service reminders, supply forecasting, backup verification or operator training. Verify effectiveness through later records rather than closing an action on a promise.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .